$LEGN News

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68

JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33

RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56

Legend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year Data

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Can Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth?

Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Legend Naming Novartis Executive as CEO

'Legend Naming Novartis Executive as CEO' - Wall Street Journal

Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

Legend Biotech To Present Data For Its CARTITUDE-2 Trial Of CARVYKTI At 23rd International Myeloma Society Annual Meeting

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

Legend Biotech (LEGN) Heads To Morgan Stanley Conference, Is The 57% Valuation Gap Justified?

Legend Biotech (LEGN) Stock May Be Undervalued Despite A 70% 3 Year Fall

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference